Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Novel STAMP Inhibitor Passes First Phase III Test In CML

Asciminib Could Be New Option For Resistant Patients

Executive Summary

Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.

You may also be interested in...

Novartis Builds On Its Legacy With Scemblix Approval For CML

US FDA approval means a new commercial opportunity in CML, where despite the success of older medicines, patients still fail on therapy.

Keeping Track: US FDA Approves Novartis’ Scemblix; Lilly Submits Tirzepatide, Withdraws Tanezumab

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance

Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts